Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma
Stopped 0 participant accrual
Conditions
- CD19 Positive
- CD22 Positive
- Minimal Residual Disease
- Progressive Disease
- Recurrent B Acute Lymphoblastic Leukemia
- Recurrent Chronic Lymphocytic Leukemia
- Recurrent Non-Hodgkin Lymphoma
- Refractory B Acute Lymphoblastic Leukemia
- Refractory Chronic Lymphocytic Leukemia
- Refractory Non-Hodgkin Lymphoma
Interventions
- BIOLOGICAL: Autologous CD19/CD22 Chimeric Antigen Receptor T-cells
- DRUG: Cyclophosphamide
- DRUG: Fludarabine
Sponsor
M.D. Anderson Cancer Center
Collaborators